TAIPEI and SAN DIEGO, March 3, 2026 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced the signing of a major strategic Memorandum of…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
